Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

Table 1 Transition probabilities used in the model

Time period	RAN PRN	RAN T&E	AFL
Year 1	RESTORE [26]	NMA [34] + RETAIN [35]	NMA [34]
Year 2	RESTORE extension [33]	Assumption (same as RAN PRN)	Assumption (same as RAN PRN)
Year 3	RESTORE extension [33]	Assumption (same as RAN PRN)	Assumption (same as RAN PRN)
Year 4+	Natural history [36, 37]	Natural history [36, 37]	Natural history [36, 37]

NMA network meta-analysis; RAN PRN ranibizumab pro re nata; RAN T&E ranibizumab treat and extend; AFL aflibercept

ISSN: 1478-7547